Research indicates that AGP is more stable and predictive of future CVD risks, such as hypertension and metabolic syndrome in young individuals, than hs-CRP (48), while a review study supports that biomarkers such as GlycA and GlycB could be superior for early detection and prediction of cardiometabolic diseases and inflammation (49). This evidence concerns the gene MAP3K14 and Hypertension.